Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Disease Awareness Ads, Not Ban On DTC, Is Best Marketing Path – Morris

Executive Summary

A ban on direct-to-consumer advertising may have the unintended consequence of shifting marketing dollars into less transparent promotional vehicles, consultant Louis Morris said during a Pharmaceutical Marketing Partnerships Institute meeting in Philadelphia July 25

You may also be interested in...

FDA Ad Division Letter Surge Shows Focus On Prominence Of Risk Information

An upcoming FDA draft guidance on fair balance in promotional materials could benefit manufacturers following a spate of warning letters from the agency's ad division citing the prominence of risk information

PhRMA To Unveil DTC Guidelines In August; Board Gives Preliminary Approval

The Pharmaceutical Research & Manufacturers of America expects to have voluntary guidelines for direct-to-consumer advertising in place by August

Bristol’s DTC Moratorium Will Affect Muraglitazar, Abatacept Launches

Muraglitazar and abatacept are likely to be the first Bristol-Myers Squibb products significantly affected by the company's recent moratorium on direct-to-consumer advertising during a drug's first 12 months on the market

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts